You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
同源康醫藥-B(02410.HK)擬折讓19%配股總籌1.57億港元 加碼研發與商業化佈局
格隆匯 07-29 06:38

格隆匯7月29日丨同源康醫藥-B(02410.HK)發佈公吿,2025年7月28日,公司與配售代理(即中信證券)訂立配售協議,據此,配售代理有條件同意作為公司的配售代理,按盡力基準促使承配人按每股配售股份17.01港元的配售價購買923萬股配售股份。預期配售代理將促使不少於6名承配人(將為專業、機構或其他投資者)認購配售股份。

假設於本公吿日期至交割日期期間已發行股份數目並無變動,則配售事項項下的923萬股配售股份相當於本公吿日期現有已發行H股數目的約2.52%及現有已發行股份數目的2.49%,及經配發及發行配售股份擴大後的已發行H股數目的約2.46%及已發行股份數目的約2.43%。每股配售股份17.01港元的配售價較7月28日(即最後交易日)在聯交所所報的收市價每股H股21.0港元折讓約19.00%。

假設所有配售股份獲悉數配售及待完成後,預期配售事項最高所得款項總額及所得款項淨額將分別約為1.57億港元及1.55億港元。公司擬按如下方式分配配售事項所得款項淨額:(i)配售事項所得款項淨額的約60%用於現有管線的研發及商業化;(ii)配售事項所得款項淨額的約30%用於加強其內部研發技術能力及擴展其產品組合;及(iii)配售事項所得款項淨額的約10%用於營運資金及一般企業用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account